BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
Erfolgreiche ePaper selbst erstellen
Machen Sie aus Ihren PDF Publikationen ein blätterbares Flipbook mit unserer einzigartigen Google optimierten e-Paper Software.
Böhle A., Schäfer I., Ulmer A.J., Rüsch-Gerdes S., Flad H.D., Jocham D. (1995)<br />
Standardisierter Vergleich der immuntherapeutischen Potenz verschiedener Stämme<br />
von Bacillus Calmette-Guérin<br />
Urologe A, 34: (Suppl .), 17 (Abstr .)<br />
Böhle A., Durek c., Schäfer I., Brandau S., Ulmer A.J., Flad H.D., Jocham D. (1998)<br />
Die <strong>BCG</strong>-aktivierte Killerzelle: Untersuchung spezifischer Erkennungs- und<br />
Tötungsmechanismen zur Charakterisierung des Wirkprinzips der intravesikalen<br />
Immuntherapie mit Bacillus Calmette-Guérin .<br />
Akt . Urol ., 29: 157-187 .<br />
Böhle A., Jocham D. (2000)<br />
Intravesical immunotherapy with Bacillus Calmette-Guérin . Facts figures and results<br />
Urban & Fischer, München, Jena<br />
Brake M., Loertzer H., Horsch R., keller H. (2000)<br />
Recurrence and progression of stage T1, Grade 3 transitional cell carcinoma of the bladder<br />
following intravesical immunotherapy with bacillus calmette-guérin\NLN\<br />
J . Urol ., 163: 1697-1701<br />
Bretton P.R., Herr H.W.,Whitmore W.F., Badalament R.A., kimmel M., Provet J.,<br />
oettingen H.F., Melamed M.R., Fair W.R. (1990)<br />
Intravesical Bacillus Calmette-Guérin therapy for in situ transitional carcinoma involving the<br />
prostatic urethra<br />
J . Urol ., 141: 853-856<br />
Brosman S.A. (1982)<br />
Experience with Bacillus Calmette-Guérin in patients with superficial bladder carcinoma<br />
J . Urol ., 141, 853-856<br />
Brosman S.A. (1985)<br />
The use of Bacillus Calmette Guérin in the therapy of bladder carcinoma in citu<br />
J . Urol ., 134: 36-39<br />
Brosman S.A. (1992)<br />
Bacillus Calmette-Guérin immunotherapy<br />
Urol .Clin .N .Am ., 19: 557-564<br />
Bui t.t., Schelhammer P.F. (1997)<br />
Additional Bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an<br />
initial complete responce<br />
Urology, 49 (5): 687-691<br />
catalona W.J.,Hudson M.A., Gillen D.P., Andriole G.L., Ratliff t.L. (1987)<br />
Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guérin therapy for<br />
superficial bladder cancer<br />
J . Urol . 137: 220-224<br />
chapman P.B. Houghton A.N. (1993)<br />
Non-antibody immunotherapy of cancer<br />
Curr . Opin . Immunol 5: 726-731<br />
cheng L., cheville J.c., Neumann R.M., Leibovich B.c., egan k.S. Spotts B.e.,<br />
Bostwick D.G. (1999)<br />
Survival of patients with carcinoma in situ of the urinary bladder<br />
Cancer, 85: 2469-74<br />
clark P.e., Streem S.B., Geisinger M.A.<br />
13-Year Experience With Percutanceous Management of Upper Tract Transitional Cell<br />
Carcimoma . J . Urol ., 161: 772-776<br />
coe J.e., Feldmann J.D. (1966)<br />
Extracutaneous delayed hypersensitivity, particularly in the guinea pig bladder<br />
Immunol ., 10: 127-136<br />
63
Change language